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1.  Executive summary 
 
Chronic kidney disease is a common and treatable condition associated with 
extremely high cardiovascular mortality rates(1).  The reasons for this mortality are 
poorly understood, but it is likely to be related to the extensive vascular calcification 
that develops in this population.   Calcification (in particular medial wall calcification, 
also called Monckeberg‟s sclerosis) and consequent stiffening of the vasculature 
leads to increased pulse wave velocity which has been shown to be associated with 
increased mortality rates (2, 3).   We propose that the link between increased pulse 
wave velocity and mortality may well be as a result of central aortic blood pressure 
and would like to measure this in our dialysis population.  Central aortic blood 
pressure has recently been shown to be an important factor in determining 
outcomes based on the differential effects of antihypertensive drugs (4), but this has 
not been studied in dialysis populations or in Africans.  There is also some evidence 
that modification of treatment according to vascular risk can improve outcomes.   
Additionally, there is recent evidence for the validity of simple measures of vascular 
calcification via use of plain radiographs instead of expensive cardiac CT and we 
would like to explore this possibility further (5). 
This is a cross sectional study of the prevalence of vascular calcification, both in the 
abdominal aorta and the coronary circulation, and their effects on central aortic 
blood pressure, ambulatory blood pressure and left ventricular mass in prevalent 
dialysis patients being treated at the Groote Schuur Hospital Renal Unit and at the 
University of Cape Town Private Academic Hospital (UCT PAH).  Assessment of 
calcification will be done by means of plane abdominal radiograph as well as cardiac 
CT while central aortic pressure, ambulatory blood pressure and radial 
augmentation index will be measured via the BPro® Radial Pulse Wave Acquisition 
Device and A-PULSE CASP® Software (HealthStats) system.  Left ventricular 
hypertrophy will be assessed via electro- and echocardiography. 
The results of this study will provide us with important information about our local 
population which will inform us as to their extent of disease.    Ideally, we would like 
to do a longitudinal follow-up with repeat assessments done after 12 months but this 
will be dependent on funding.  Future treatment decisions, based on this risk profile, 
will therefore be assessed and ultimately, this should impact positively on patient 
outcomes. Additionally, we hope to validate simple measures of calcification as 











2. Relevance of this study
To our knowledge, no study has examined the influence of vascular calcification on 
central aortic and ambulatory blood pressure in dialysis patients.  As discussed 
above, this may provide us with important information that may ultimately improve 
care for dialysis and pre-dialysis patients.   
The assessment of extra-coronary calcification and vascular function in relation to
coronary calcification has not been performed in Africa where a younger dialysis
population exists and where genetic and environmental influences may affect
mineral metabolism and hence cardiovascular risk. Many environmental differences
exist that could account for differences in vascular and bone health such as
exposure to sunlight and Vit D use, diet and salt consumption, dialysis quality,
membrane type, aluminium toxicity, iron loading, water strontium content and limited
access to more effective phosphate binders (6).
Validation of a simple method for the assessment of vascular calcification will
provide clinicians in our environment with a cost-effective means of determining a
vascular risk profile from which patients stand to benefit the most as compared with 
more costly investigations. Determining a baseline calcification score in this way will
also allow researchers to design prospective trials comparing progression of disease
based on differing therapies and assess mortality prediction through follow up as 
recommended in the recent KDIGO report (7). Therefore, this is likely to add 
information to traditional risk prediction models which cannot explain all of the
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1. To determine the prevalence of vascular calcification in prevalent dialysis 
patients in the Groote Schuur Hospital and UCT PAH Renal units as 
assessed by coronary CT and abdominal radiograph. 
2. To determine if vascular calcification influences the central aortic blood 
pressure, augmentation index and 24 hour ambulatory BP in dialysis 
patients. 
3. To compare coronary calcification and central aortic blood pressure with 




1. To examine the relative contribution of comorbid illness (E.g. diabetes 
mellitus), ethnicity, age, dialysis vintage, calcium exposure, vitamin D status, 
calcium/phosphate product, blood pressure and smoking status towards 
vascular health in this cohort. 
2. To examine the effects of vascular calcification on left ventricular 
hypertrophy (LVH) as assessed by electrocardiography (ECG) and 
echocardiography.  
3. To examine the differences (if any) between ethnicity and dialysis modality, 
and vascular health. 
 
Ideally, we would like to do a longitudinal study with reappraisal after 12 months 




















1. Study design and rationale 
 
The study will take the form of a cross-sectional survey of all prevalent 
haemodialysis and peritoneal dialysis patients ≥ 18 years of age at Groote Schuur 
Hospital and UCT PAH with a duration of dialysis ≥ 3 months (approximately 100 
patients).  Controls will be enrolled after advertising locally for the appropriate 
persons.  Patients will be examined and relevant data such as blood pressure (BP), 
pulse pressure, body mass index (BMI), N-N distance (sternal notch to navel 
distance) will be noted.  The presence of abdominal aortic calcification will be 
determined by lateral lumbar radiograph as described by Kaupilla (8).   Coronary 
calcium score will be determined through coronary CT scanning with the use of a 
multidetector CT scanner.  Vascular function and 24 hr ambulatory and central blood 
pressure will be assessed through radial pulse wave analysis as measured via the 
BPro® Radial Pulse Wave Acquisition Device and A-PULSE CASP® Software 
(HealthStats) system which is an FDA-approved device.  All available laboratory 
parameters such as calcium, phosphate and their product will be recorded as well 
as alkaline phosphatase and parathyroid hormone trends.  Electrocardiography and 
echocardiography will be performed to assess for the presence of left ventricular 
hypertrophy (LVH).  Controls will undergo coronary CT scanning and BPro analysis.  
Analysis of data will then be done looking for significant differences in baseline 
characteristics between populations and relating these to the degree of vascular 
calcification and the vascular functional assessment. 
The above protocol will be subject to subject to the approval of the Research Ethics 
Committee of the Faculty of Health Sciences of the University of Cape Town.  
 
2. Subject selection and enrolment 
 
Subjects will be approached within the dialysis unit at Groote Schuur Hospital and at 
the UCT PAH.  Controls will be selected after advertising appropriately.  We will 
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Screening examinations will be used to determine the eligibility of each candidate for 
study inclusion.  
 
Inclusion Criteria 
 Adult patients receiving haemo- and/or peritoneal dialysis for ≥ 3 month‟s 
duration.  
 Ability and willingness of subject or legal guardian/representative to provide 
informed consent 
 Men and women age  18 years 
 Controls to have a normal clinical examination, normal urine dipstick and 
estimated GFR ≥60ml/min 
  
Exclusion Criteria 
 Planned or current pregnancy within the next 6 months due to radiation risks 
(subjects to have a documented negative pregnancy test prior to inclusion) 
 
It should be noted that some conditions will exclude individual subjects from certain 
of the tests, but these subjects will still be included for analysis of available data.  
The absence of both radial pulses or sustained arrhythmia precludes BPro analysis.  
Previous coronary artery bypass or stenting will preclude coronary CT. 
 
Sample Size Calculation 
In previous studies, the prevalence of coronary calcium score ≥1000 was 21% (9).  
In our population, it is likely that the prevalence of coronary calcium score ≥1000 will 
be lower due to the younger age of our cohort and lower prevalence of diabetes 
(selection bias due to acceptance onto the hospital dialysis programme criteria).  
Thus, if we assume a prevalence of this outcome to be between 10 and 21%, then a 
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One Proportion: Power Calculation
Test on One Proportion (H0:  Pi = Pi0)
Power vs. N (Pi = 0.21, Pi0 = 0.1, Alpha = 0.05)















Power implication of different sample sizes presented in the above graph. 
 
Calculation of sample size of control group: 
There is no published data on coronary c lcification scores in the South Africa 
population.  We can, therefore, only make estimates based on previously published 
studies from abroad.  The data published in various studies has not been reported in 
the same format and so in choosing the difference between cases and controls, we 
have chosen to use the proportion of patients with a coronary calcium score of 
<100.   
In a study published in Brazil (10), 101 prevalent haemodialysis patients were 
analysed.  Importantly, the mean age of the study was 48 which may compare 
adequately with our younger population versus most other studies where the 
average age has been significantly older.  In this study, the proportion of patients 
with a coronary calcium score of <100 was 48%. 
In the Multi-Ethnic Study of Atherosclerosis (MESA) (11), the distribution of coronary 
artery calcium score by race, gender, and age was evaluated in asymptomatic  
individuals who were apparently free of cardiovascular disease.  These data give us 
some idea of percentiles for coronary calcium score in a healthy, non-selected 
population similar to what we could expect for our controls.  Given that the 90th 
centile for coronary calcium score in those aged 45-54 years  in whites was 8 for 
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safe to assume that the proportion of both populations with a coronary calcium score 
<100 is at least 90%. 
We have therefore used the above proportions to predict the sample size of controls 
required for our study assuming a case series of 75 patients.  (This was based on 
the original power calculation stating a minimum of 70 patients is required for a 
predicted frequency of severe calcification, CAS >1000, between 10 and 21%)  
Therefore, for a case series of 75 patients, we can expect to need at least 13 
controls.  These should be matched for age, sex and smoking status but be free 
from Chronic Kidney Disease (normal urine dipstick and estimated GFR) and other 
known cardiovascular disease.  Given the uncertainty surrounding our population, 




3. Study enrolment procedures 
 
Once a candidate for study entry has been identified, details of the study will be 
carefully discussed with the subject.  All potential participants will be informed of the 
purpose, scope and details of the study with the aid of an approved patient 
information leaflet. The subject will be asked to read the information leaflet and sign 
the informed consent form.  Ample time will be given to the subject to ask questions 
and review procedures. Patients will be given an original copy of the patient 












Subjects from whom informed consent has been obtained, and who are eligible for 
the study, will be given a patient identification number (PID) and data will be entered 
onto protocol specific case report forms and then entered into the database.   
4. Clinical and Laboratory Evaluations
The cohort will be investigated as described below. All subjects will be encouraged
to undergo all tests and procedures. Radial pulse wave analysis, ambulatory blood 
pressure and echocardiography will be conducted in Groote Schuur Hospital but
patients will be required to travel to the UCT private academic hospital (1 floor
down) for the performance of lateral abdominal radiograph and coronary CT scan.
Screening/Entry Evaluations will be done on the same day. All imaging and data
collection will be collected within a total period of one month from enrolment. It is 
envisaged that subjects will be required to attend between 2 and 3 additional visits 
for study purposes between regular dialysis days. Transport costs will be
compensated accordingly. Controls will be required to have a full clinical
examination, urine dipstick test and serum creatinine to exclude chronic kidney
disease or other chronic illness prior to inclusion
4.1 Medical Questionnaire
An investigator will complete a detailed medical questionnaire. Details of age, sex,
self reported population group, dialysis vintage, phosphate binder, smoking history
and history of diabetes mellitus, hypertension, dyslipidaemia, cardiovascular history 
including angina, heart failure, myocardial infarction, revascularization, vascular 
surgery and current medications will be recorded and clinic records screened for all
supportive data including drug history. Trained investigators will administer the
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4.2  Clinical Assessment 
 
 Physical Examination:   
A limited physical examination will be performed and relevant information 
such as blood pressure (BP), pulse pressure, pulse rate and presence and 
site of AV fistula will be recorded.  BP will be measured in the seated 
position in the arm that does not contain an arteriovenous fistula after a 
minimum period of 5 minutes rest with the mean of the last two readings 
once stable readings are achieved as per the South African Hypertension 
Society guidelines (12).  
 
 Height:  Recorded in cm.  
 
 Weight:  Recorded in Kg. 
 





These tests will be performed at the 2 Military Hospital in Wynberg.   
 
4.3.1 Lateral Abdominal Radiograph 
The standard technique of exposing the lateral lumbar spine in standing position 
(with 100 cm film distance, 94 KVP, and 33–200 mAs) will be used.  The radiograph 
should include the last two thoracic vertebrae and the first two sacral vertebrae with 
a minimum of 4cm soft tissue being visible anterior to the lumbar spines.  The 
estimated dose of radiation is 1mSv. The approach to be used in terms of scoring 
calcific deposits in the abdominal aorta will be very similar to that described by 
Kaupilla in 1997 (See appendix A for full description) (8).  The radiographs will be 
read by two investigators who should reach consensus on every radiograph. Only 
the segments of abdominal aorta in front of the first to the fourth lumbar vertebra will 
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calcified plaque (0: none; 1: <1/3rd of segment length; 2 ≥1/3rd but < 2/3rds of 
segment length; 3: ≥2/3rds of segment length) identified along the anterior and 
posterior profiles of the aorta in front of each of the lumbar vertebrae.  Using this 
numerical grading, each patient will be assigned a score between 0 and 24 with 
higher scores indicating a greater degree of calcification of the abdominal aorta.  
The abdominal aortic calcification scores will be divided into approximate tertiles for 
statistical analysis purposes (scores of 0, 1–6 and ≥7). 
 
4.3.2 Coronary CT 
Spiral CT will be used to determine coronary calcium score using the volume 
method which has been validated and described in detail previously (13) (See 
Appendix B for full description).  The estimated dose of radiation is 1-2.5mSv.  The 
total yearly dose of radiation recommended for non-medical personnel is 5mSv (5).  
The data acquisition parameters will be: 120 kVp, 400 mAs, nominal slice width 2.5 
mm (effective width 3.2 mm), gantry rotation time 0.5 s, table feed 7.5 mmus [pitch 
0.375 (34 slices per rotation)]. Data will be reconstructed with a 1808 linear 
interpolation algorithm providing a temporal resolution of 270 ms, retrospective ECG 
gating during diastole, 1.3 mm longitudinal increment, 5123512 matrix, field of view 
25 cm2, medium body (C) filter, and no edge enhancement. Data will then be 
transferred to a workstation and analysed with appropriate software.  The scans will 
be read by an experienced investigator.  Coronary artery calcium scores will be 
divided into three levels (<100, 100–999, and ≥1000) based on cut points that have 
been shown to be associated with increased cardiovascular disease incidence in 
general population studies. 
 
4.4  Echocardiography 
Understanding the limitations of its use, assessment of left ventricular mass will be 
done via use of M-mode echocardiography and this will be calculated using the 
Penn convention as described previously: 
 LV mass(Penn) = 1.04 ([LVIDD + PWTD + IVSTD]3- [LVIDD]3) -13,6 (14).  All 
echocardiograms will be done by the same experienced investigator. Left ventricular 
hypertrophy will be defined as >125 g/m2 in males and >110 g/m2 in females as per 
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4.5  Electrocardiography 
All patients will have a resting electrocardiogram (ECG) performed.  These will be 
analysed by two experienced investigators who should reach consensus on the 
interpretation of each ECG.  Both the Sokolow-Lyons index (SV1 + RV5–6 >38 mm = 
LVH) and Cornell voltage QRS duration product (>2440 mm*ms = LVH) will be 
reported on quantitatively, and the presence or absence of left ventricular 
hypertrophy noted as defined by the ESH guidelines. 
 
4.6 Ambulatory Blood Pressure and Pulse Waveform Analysis 
Vascular function and 24 hr ambulatory and central blood pressure will be assessed 
through radial pulse wave analysis as measured via the FDA-approved BPro® 
Radial Pulse Wave Acquisition Device and A-PULSE CASP® Software 
(HealthStats) system.  The BPro™ has been validated against the AAMI and ESH 
protocols and passed both validations (16).  It carries a CE mark and is approved for 
clinical use by the FDA.  The BPro™ records pressure wave forms calibrated to the 
brachial BP through use of an FDA-approved oscillometric monitor (MC300, 
HealthStats) and samples up to 96 X 10 second blocks of time, over 24 hours.  This 
will provide a 24 hour profile and summary of an individual‟s systolic, diastolic and 
mean arterial pressures.  It also gives information on BP dipping status.  The A-
PULSE CASP® software makes use of an “npoint forward moving average” (NpMA) 
method to calculate central aortic systolic pressure and radial augmentation index.  
The device has been validated against the Sphygmocor™ device using all CAFÉ 
study data and the correlation was r2=0.993.  Additionally, central aortic pressures 
were recorded in vivo at the aortic root using a Millar‟s SPC‐454D tonometer 
(Millar‟s instruments, Texas U.S.A) in 20 patients undergoing routine cardiac 
catheterization and the pressures compared with that obtained by the BPro device.  
The correlation between the BPro™ readings of CASP and the direct measurement 
of aortic CASP was r2=0.9835.  (Unpublished as yet) 
Practically, the device will be applied as a wrist watch on the arm that does not 
contain an AVF.  It will then be calibrated to brachial blood pressure after the 
individual has rested for 5 minutes via use of the MC3000 oscillometric device.  The 
device is then connected to the software and real time pulse wave morphology 
captured.  Thereafter, it will be worn by the individual for a 24 hour period 
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4.7 Blood Investigations 
We will also record all available laboratory parameters such as haemoglobin, 
calcium, phosphate, alkaline phosphatase, 25-OH Vit D3 and parathyroid hormone 
for the last two years on each patient where such data is available.  This information 
is part of standard dialysis care for all patients in the unit and therefore no 
venepuncture should be necessary as part of the study.  However, it may be 
necessary to do some tests if the test has not been performed by the dialysis unit 
already.  Controls will have a serum creatinine with estimated glomerular filtration 
rate done and analysed at a local private laboratory. 
 
5. Criteria for Discontinuation 
 
 Request by subject to terminate treatment 
 Clinical reasons considered serious or life-threatening by the physician  
 Subject repeatedly non-compliant with visits and procedures 
 Withdrawal of consent 
 
6. Analysis of Data and Statistical Considerations 
 
 The primary comparison will be between subjects that have significant vascular 
calcification and those that do not.  This will be done via the cross-sectional design 
of the study.  Variables that will be considered include: 
 Age, smoking status and population group 
 Dialysis vintage 
 Diabetes Mellitus and other comorbid illness 
 Phosphate binder and Vitamin D used and duration thereof. 
 Calcium, phosphate, ALP,  PTH and Hb values 
 Radiographic investigation (radiographs, CT, Echo) 
 Central aortic blood pressure, radial augmentation index and the presence of 
LVH 
 
We will produce summary statistics (mean, median, standard deviation, and 











be used to compare values obtained for patients with and without vascular 
calcification.   Logistic univariate and multivariate analysis will be employed to 
determine differences in risk factors (if any) for vascular calcification between these 
groups. 
7. Data Collection and Monitoring and Adverse Event
Reporting
Case report forms (CRF) will be provided for each subject. Subjects will not be
identified by name on data spreadsheets or on any external communication.
Subjects will be identified by the patient identification number (PID)
8. Ethical Considerations
Research Ethics Committee (REC) Review and Informed Consent
This protocol and the informed consent document and any subsequent modifications
will be reviewed and approved by the REC responsible for oversight of the study. A
signed consent form will be obtained from the subject (or parent, legal guardian, or
person with power of attorney for subjects who cannot consent for themselves, such
as those below the legal age of consent). The consent form will describe the
purpose of the study, the procedures to be followed, and the risks and benefits of
participation. A copy of the consent form will be given to the subject, parent, or legal
guardian, and this fact will be documented in the subject‟s record. This protocol
complies with the latest version of the Declaration of Helsinki (2008) and the 
Department of Health: Ethics in Health Research: Principles Structures and 
Processes (2004). 
Perceived Risks and Benefits
There are very few perceived risks involved in the study the main ones being 
additional radiation via CT and abdominal radiograph.  However, the exposure from 
these investigations is well below the recommended additional yearly exposure of 5 
mSv as discussed above.  In fact, all of the investigations we are performing would 
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We feel that the information gained through our study will impact positively on our 
patient care.  Any problems identified through investigation will be made known to 
the participant and with consent, to the doctor responsible for their care. 
 
Subject Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records that leave the 
site will be identified by coded number only to maintain subject confidentiality.  All 
records will be kept locked.  All computer entries and networking will be done with 
coded numbers only in order to protect confidentiality. Clinical information will not be 
released without written permission of the subject, except as necessary for 
monitoring by the IRB or the Department of Health. 
The study may be discontinued at any time by the IRB, the Department of Health, or 
other government agencies as part of their duties to ensure that research subjects 
are protected. 
 
9. Biohazard Containment 
 
As the transmission of HIV and other blood-borne pathogens can occur through 
contact with contaminated needles, blood, and blood products, appropriate blood 
and secretion precautions will be employed by all personnel in the drawing of blood 




























2010 January to April Protocol development, funding applications, 
development of radiographic reporting 
techniques and questionnaire as well as local 
ethics committee approval 
 
2010 May    Collection of data begins 
 
2011 May   Submit annual progress report to IRB 
 
2011 July to September  Analysis and reporting of data 
 




   
Study-related Costs*  
 Research Nurse R 184 800.00 
 Data typist and statistician R 45 000.00 
 Lateral Lumbar Radiograph (100 pts @ R266 each) R 26 600.00 
 Echocardiography (100 patients @R670 each) R 67 000.00 
 Coronary CT (100 patients @ R2827 each) R 282 700.00 
 
BPRO Radial pulse wave system (2 units at R60 000 
each) R 120 000.00 
 Travel costs (100 patients @ R50 each for 6 visits) R 30 000.00 
 Consumables R 10 000.00 
 Equipment R 20 000.00 
 Travel and conference attendance R 20 000.00 
   
 TOTAL R 806 100.00 
 
*Expenses calculated according to National Reference 
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Appendix A:  (Method of assessing aortic calcification 
as per Kaupilla (Kauppila et al. 1997) 
Kaupilla‟s approach as described in their article as 
follows:  “was to assess both the location and severity of 
calcific deposits in relation to segmental lumbar arteries 
and we assessed aortic calcifications at each vertebral 
segment. Calcific deposits were regarded as present if 
densities were visible in an area parallel to the lumbar 
spine and anterior to the lower part of the spine. Aortic 
densities at the upper part of the lumbar spine often 
overlapped the vertebrae, as the abdominal aorta in the 
L1-L2 region is often lateral to the spine, while the lower 
abdominal aorta in the L3 and L4 region is situated 
anterior to the spine. Densities overlapping the vertebrae 
were scored present only if they extended from or formed 
a clear pattern with those of the lower part of the aorta.” 
“Lesions were graded as follows: 0, no aortic calcific 
deposits; 1, small scattered calcific deposits filling less 
than 1:3 of the longitudinal wall of the aorta; 2, one third 
or more, but less than two thirds or more of the 
longitudinal wall of the aorta calcified; 3, two thirds or 
more of the longitudinal wall of the 
aorta calcified.  Individual level-specific severity scores 
were summarized to yield three different composite 
scores for aortic calcifications.  In the affected segments 
score (0–4), the number of individual aortic segments 
which showed any calcification were calculated. In the 
anterior and posterior affected score (0–8), the number of 
individual aortic segments, both anterior and posterior, 
which showed any calcification were summed. In the 
antero–posterior severity score (0–24), the scores of 
individual aortic segments both for the posterior and 
anterior wall were summed. 
















Appendix B (Description of Coronary 
Calcium Score Method as per (Moe et al. 
2003)): 
“CT scans were performed with the quad-slice technique 
on the model MX 8000 scanner (Philips Medical Systems, 
Cleveland, OH). The data acquisition parameters were: 
120 kVp, 400 mAs, nominal slice width 2.5 mm (effective 
width 3.2 mm), gantry rotation time 0.5 s, table feed 7.5 
mmus [pitch 0.375 (34 slicesurotation)]. Data were 
reconstructed with a 1808 linear interpolation algorithm 
providing a temporal resolution of 270 ms, retrospective 
ECG gating during diastole, 1.3 mm longitudinal 
increment, 5123512 matrix, field of view 25 cm2, medium 
body (C) filter, and no edge enhancement. Data were 
transferred to a workstation and analysed with HeartBeat-
CS software (MX View, Marconi Medical Systems, 
Cleveland, OH). On the basis of the ECG tracing, the 
software program automatically selected a reduced set of 
diastolic images from each cardiac cycle. The proximal 
coronary arteries were scored, beginning with the first 
image in which a coronary artery was seen (usually the 
left anterior descending) and continuing for 6 cm along 
the long axis of the patient [6]. All pixels with density P130 
Hounsfield units (HU) were highlighted automatically in 
colour on the images. The observer placed an electronic 
region of interest (ROI) around each highlighted CAC and 
assigned one of four locations to each calcified plaque: 
left main, left anterior descending (LAD), circumflex or 
right coronary artery. Branches of the LAD, circumflex and 
right coronary arteries were considered parts of those 
arteries. The descending aorta was evaluated over the 6 
cm in the z-axis direction. A minimum plaque area of 0.5 
mm2 was used to reduce errors due to noise.”Calcium 
scoring by volume will be used. “This method, called 
average-continuous, uses a weighting factor (F)s(Au100)–
0.5, where A is the average density of each plaque on 
each image. The score for 
each plaque is calculated by multiplying the area of each 
plaque in mm2 (to generate a volume determination) by 
the weighting factor. The score for the entire specimen 
equals the sum of the scores for each plaque. As above, 
this score is then multiplied by 1.07. This technique is 
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Vascular calcification and stiffening are common in dialysis patients and are 
associated with adverse cardiovascular outcomes. Vascular calcification in ESRD
appears to be linked to abnormal bone physiology and the risk factors for its
development (such as calcium load and ethnicity) require investigation. It may be
possible to assess for the presence of vascular calcification by simple and
inexpensive means but this requires validation in our context. Furthermore, the
prevalence of vascular calcification in African patients is not known. The reasons 
for increased cardiovascular mortality in CKD remain incompletely understood.
Although the pathophysiology is likely multifactorial, alterations in central
haemodynamics may play a significant role in this and this requires further
investigation.
Cardiovascular mortality in end stage renal disease
Chronic kidney disease (CKD), is both common, harmful and treatable (1). It is
estimated that approximately 10% of the world‟s population suffer from CKD (2).  
While there is no reliable estimate of the burden of CKD in South Africa, it is thought
to be similar to global trends. Even more alarming is the 67% increase in premature
adult deaths secondary to kidney disease in South Africa in just 7 years from 1999
to 2006 (3). Haemodialysis (HD) patients in particular, experience extremely high
rates of cardiovascular mortality, 20 – 30 times higher than that of age-matched
peers (4, 5). Almost certainly, this is in large part secondary to accelerated vascular
disease comprising both arteriosclerosis and atherosclerosis. However, the reasons
behind the rapid development of this state are incompletely understood and are not
entirely explained by traditional risk factors. While traditional risk factors may
account for much of the mortality in the uraemic state, many novel cardiovascular
risk factors exist such as vascular calcification, raised aortic pulse wave velocity 
(PWV), raised central aortic systolic pressure (CASP) and loss of nocturnal blood
pressure (BP) dipping that could explain the high incidence of cardiac death (6). 
This has been especially highlighted by the minimal impact of statin therapy to 











(ESRD)(7-9) .   These data have called into question traditional beliefs about risk 
factors for cardiovascular disease in the context of CKD and there has thus been a 
call for more intense research in this area to better define contributing risk factors 
and the underlying process.  One such process is the rapid development of arterial 
calcification in patients with end-stage kidney disease. 
Vascular Calcification in renal disease 
Vascular calcification is extremely common in CKD-5D and reported prevalence 
rates are >80% in studies published in Europe and in the United States (10, 11).
While the pathogenesis is certainly complex, it involves endothelial dysfunction,
abnormalities of mineral metabolism and altered levels of endogenous inhibitors of
calcification (12). Vascular calcification may localise to the intima (often in
association with atherosclerosis) or to the media (common in renal disease and 
related to disordered mineral metabolism) or both. While at lower risk of mortality
than those with intimal calcification, patients with medial calcification are still at
much higher risk of death than age-matched peers (13). Most data relates to
haemodialysis populations. Very little is known about the relative risks of vascular 
calcification with different dialysis modalities however it seems that vascular
calcification is also highly prevalent in peritoneal dialysis (PD) populations (14).  
Established risk factors for the development of VC in published studies include age,
time on dialysis, the presence of diabetes, a history of vascular disease and raised
calcium/phosphate product (11, 15). Unfortunately, there is no published data
describing the prevalence of VC in Sub-Saharan Africa.
The cost of calcium loading 
There appears to be a strong link between the presence of vascular calcification and 
chronic kidney disease bone mineralisation disorders (CKD-BMD) (16).   In 
particular, the presence of low bone turnover as determined by bone biopsy appears 
to correlate with the extent of extra-coronary calcification (17).   Additionally, calcium 
load (orally, or through dialysate exposure) has been shown to correlate with 
vascular calcification and its progression in haemodialysis patients (18, 19). 
Moreover, the dosage of calcium containing phosphate binders has been shown to 
have the greatest impact on vascular calcification and stiffness in the presence of 











of adynamic bone disease despite the reduction in aluminium exposure over time 
(20). It is thought by many investigators that this may be due to excessive use of 
calcium based phosphate binders and vitamin D analogues and as such, it has been
proposed that judicious management of calcium homeostasis in CKD could delay
the development of vascular calcification and hence lower mortality (21).
Sevelamer, a non-calcium containing phosphate binder, has been shown in two
randomised controlled trials to retard the progression of vascular calcification in 
haemodialysis (HD) patients (18, 19, 22) and in one study (23) was associated with 
lower mortality in incident HD populations. The mechanism for this effect may be
due to improvements in bone turnover as shown in a prospective study of
Lanthanum Carbonate, another non-calcium containing phosphate binder (24). The
reduction in coronary calcification with sevelamar use was not found in a third study
(25) but this may have been due to inclusion of patients with other well established 
risks for calcification apart from CKD (26).
Patients at the highest risk for death (those with prominent vascular calcification)
may stand to benefit the most from these costly drugs which are not widely available 
in resource poor settings. However, it has been suggested that further studies are
needed before firm recommendations to this effect can be made (27). Currently, the
latest guidelines from the KDIGO group have suggested restricting the dose of
calcium-based phosphate binders in the presence of arterial calcification and/or
adynamic bone disease and/or if serum PTH levels are persistently low (28).
Endogenous inhibitors of calcification
There exist several endogenous circulating or tissue bound factors that inhibit the
development of vascular calcification in vivo. These include factors such as matrix
gla protein, fetuin A and osteopontin. Levels of these inhibitors have been shown to 
be altered in renal disease and may therefore predispose to the development of VC
(29). There is no published data on these inhibitors in African patients.
The role of ethnicity and geography 
There exist significant differences between the rates of coronary artery calcium 
score in white populations of different continents (30).  Furthermore, there exist 
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different ethnic groups.  It has been suggested that some of these differences could 
be accounted for by differing vitamin D metabolism (33).  Despite this, a recent 
cross sectional survey of prevalent dialysis patients showed no differences in 
markers of vasculopathy (PWV), Coronary calcium score and Thoracic calcification 
as measured by Electron Beam CT) between white and black subjects.  Importantly, 
both centres in this survey were in the United States (34) and it remains to be 
determined whether this holds true in South Africans. 
 
The effects of Vascular calcification: stiffening and the link with mortality 
The presence of vascular calcification is a strong predictive marker for 
cardiovascular (CVS) mortality in any population and vascular calcification is 
particularly prevalent in the dialysis population where CVS disease accounts for 
much of the mortality (35-37).  Coronary artery calcium presence and the coronary 
artery calcium score (as determined by CT) are strongly associated with 
cardiovascular mortality in dialysis populations (13, 38).   While ischaemic heart 
disease is an important contributor to death (5.6%) in these populations, the leading 
cause of death in dialysis patients is in fact sudden cardiac arrest or arrhythmia 
accounting for 26.3% of deaths (39).  The link between vascular calcification and 
subsequent mortality is unknown but haemodynamic factors are likely to play a 
significant role.   VC is associated with increased aortic PWV (11) and this in turn, is 
associated with raised CASP and reduced coronary perfusion due to the summation 
of propagated and rapidly reflected pressure waves at the aortic root (40, 41).    
Whether vascular calcification is directly linked with central pressures is however, 
unknown since there are many determinants of aortic stiffening other than vascular 
calcification (42).  Furthermore, a damaged and stiff aorta may well be a target for 
the deposition of calcium due to exposure of calcium binding sites on fragmented 
elastin fibres.  As a result, central pressures may vary significantly from what may 
be expected based on brachial blood pressure alone and may result in the 
misclassification of many hypertensives (43).  In addition to VC, loss of the normal 
nocturnal BP drop has also been identified as a potential contributor to the high 
cardiovascular burden in CKD (44). Non-dipping status is associated with greater 
proteinuria and more rapid loss of glomerular filtration rate (GFR) in CKD (45, 46), 
and in end stage renal disease has correlated better with left ventricular mass index 











Detection of Vascular Calcification: CT as the gold standard 
Since the advent of 64-slice multidetector CT scanning, coronary calcium content
can be reliably measured non-invasively in dialysis patients. As mentioned above,
the extent of calcium presence correlates well with hard end-points and survival in
CKD-5D. Coronary CT cannot distinguish between arterial intimal and medial
calcification but does correlate well with the presence and amount of atherosclerotic 
plaque. While the presence of calcium confers a higher risk on an individual, the
abscence of any calcium is associated with a very low mid-term risk of coronary
events. Furthermore, adding the coronary calcium score to traditional risk factor
prediction models improves risk stratification (49). Of course, the major
disadvantage of coronary CT is its high expensive and lack of availability in 
resource-poor settings.
A call for accessible screening: The role of plane radiographs 
The Global Bone and Mineral Initiative Working Group of the Kidney Disease
Improving Global Outcomes (KDIGO) managed by the National Kidney Foundation
has recommended screening for the presence of cardiovascular calcification with 
simple office-based methods to make it accessible to a greater number of
nephrologists (28). This is particularly relevant to our setting in Africa where studies
are severely lacking. Additionally, validation of these methods in our population is 
required.
It has recently been shown that there exists a good correlation between coronary
artery calcium score (CAS) and the presence of abdominal aortic calcification (AAC)
as determined by lateral plane radiograph of the abdomen as well as pulse wave
velocity (PWV) (11) in developed nations. Furthermore, it has been shown that as 
with the CAS, the degree of AAC is also predictive of mortality in haemodialysis
patients (36, 50) and in transplant recipients (51). This provides an inexpensive
means to determine the presence of vascular calcification and hence risk in
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Current gaps in knowledge and reasons for our study 
To our knowledge, no study has examined the influence of vascular calcification on 
central aortic and ambulatory blood pressure in dialysis patients.  As discussed 
above, this will provide us with important information that may ultimately improve 
care for dialysis and pre-dialysis patients.   
 
There is no published data on the prevalence of vascular calcification in African 
dialysis patients.  In Africa, a younger dialysis population exists and genetic and 
environmental influences may affect mineral metabolism and hence cardiovascular 
risk.  Many environmental differences exist that could account for differences in 
vascular and bone health such as  exposure to sunlight and Vit D3 use,  diet and 
salt consumption, dialysis quality, membrane type, aluminium toxicity, iron loading, 
water strontium content and limited access to more effective phosphate binders 
(53).     
 
Validation of a simple method for the assessment of vascular calcification will 
provide clinicians in our environment with a cost-effective means of determining a 
vascular risk profile from which patients stand to benefit the most as compared with 
more costly therapy.  Determining a baseline calcification score in this way will also 
allow researchers to design prospective trials comparing progression of disease 
based on differing therapies and assess mortality prediction through follow up as 
recommended in the recent KDIGO report.  Therefore, this is likely to add 
information to traditional risk prediction models which cannot explain all of the 
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In Sub-Saharan Africa, the prevalence of vascular calcification (VC) in CKD-5D is unknown.  
We undertook to determine the effect of ethnicity on VC, the risk factors for VC, the utility 
of abdominal X-ray (AXR) in predicting coronary calcium score (CCS) and the effect of VC on 
central aortic systolic pressure (CASP) and left ventricular mass index (LVMI) in South 
African dialysis patients. 
METHODS 
74 CKD-5D patients and 20 healthy controls were studied prospectively.  All subjects 
underwent chest CT for CCS, AXR for abdominal aortic calcium score (AACS), 
echocardiography for LVMI.  Ambulatory blood pressure monitoring (ABPM) and CASP were 
generated via radial artery applanation tonometry. 
RESULTS 
Overall, 38.6% of cases demonstrated CCS ≥1. On multivariate analysis, positive predictive 
factors included age and prior cardiovascular disease.  Blacks had a median CCS of 0 (IQR 
0) while non-blacks a median CCS of 66 (IQR 383), p<0.001; controls had a CCS of 0 (IQR 
0).  Black race remained a significant negative predictor for coronary calcification after 
adjustment for known precipitants, PR = 0.14 and 95% CI: 0.0-0.53.  VC was not associated 
with any ABPM parameters; interdialytic office BP was highly predictive of ABPM (r=0.9, 
p=0.9).  Using receiver operator characteristic (ROC) curves, an AACS of >1 showed an area 
under the curve of 0.83 to predic  a CCS >10. 
CONCLUSIONS 
Black race significantly protects from VC in South African CKD-5D patients and warrants 
further study.  The AXR is a useful screening tool for CCS in our population.  VC does not 
appear to influence CASP in our population.     
Keywords: vascular calcification, ethnicity, dialysis, central aortic systolic pressure, 
applanation tonometry, ambulatory blood pressure monitoring 
 
SUMMARY OF MAIN MESSAGE IN PAPER 
Black South African CKD-5D patients appear protected against vascular calcification despite 
adjusting for known precipitants.  While it is plausible that this could be due to inherited 
differences in endogenous inhibitors of calcification, this remains to be investigated.  Lateral 
abdominal X-ray is a good screening test for coronary calcification.  VC was not associated 















Haemodialysis (HD) patients experience extremely high rates of cardiovascular mortality, 20 
– 30 times higher than that of age-matched peers (1, 2).   Coronary artery calcium (CAC) 
presence, and the coronary artery calcium score (CCS) as determined by cardiac computed 
tomography (CT), are strongly predictive of cardiovascular mortality in dialysis populations, 
(3, 4) which most often takes the form of sudden cardiac death (5).  Vascular calcification 
(VC) is evident in >80% of the dialysis population in Europe and the US (6-8).  The 
prevalence of vascular calcification in Sub-Saharan Africa is unknown.  
 
VC is associated with stiffening of the aorta and increased aortic pulse wave velocity 
(PWV).  This is associated with raised central aortic systolic pressure (CASP) and reduced 
coronary perfusion (9, 10).  Brachial pressure may thus underestimate central pressure (11).  
Whether VC is directly linked with central pressures is however, unknown since a damaged 
and stiff aorta may also be a target for the deposition of calcium (12).  CASP can be 
calculated from applanation tonometry-derived peripheral pulse waveforms thus avoiding 
invasive central pressure determination (13).  The major disadvantage of standard techniques 
(such as carotid-femoral PWV) however, is the one-dimensional static measurement 
obtained, with no information on ambulatory values or nocturnal dipping status.  Loss of the 
normal nocturnal blood pressure (BP) drop has also been identified as a potential contributor 
to the high cardiovascular burden in CKD (14) and in end stage renal disease it has 
correlated better with left ventricular mass index (LVMI) than office BP measurements alone 
(15, 16).   There have been calls for the routine use of ABPM in clinical studies of CKD 
given the lack of information on BP variability (14, 17).  
CAC is best detected on a cardiac CT scan which is very expensive and not universally 
available.  Studies from the USA have shown a reasonable correlation between CCS and the 
presence of abdominal aortic calcification (AAC) as determined by a lateral radiograph of 
the abdomen (AXR) (18).  As for coronary calcification, the degree of AAC is also 
predictive of mortality in haemodialysis patients (6, 19) and in kidney transplant recipients 
(20).  The Global Bone and Mineral Initiative Working Group of the Kidney Disease 
Improving Global Outcomes (KDIGO) has recommended screening for the presence of 
cardiovascular calcification with simple office-based methods such as echocardiogram or 
lateral abdominal radiograph to make it accessible to a greater number of nephrologists (21).    
Validation of these methods in our population is required. 
We undertook to do this by performing simultaneous cardiac CT and AXR in a prospective, 











Patient demographics were recorded in an attempt to identify risk factors for vascular 
calcification and to assess the effect of ethnicity on VC.  Furthermore, we sought to 
prospectively evaluate whether the presence of VC in our CKD-5D cohort had any 
relationship to ambulatory CASP, LVMI and nocturnal dipping status using the BPro® 
Radial Pulse Wave Acquisition Device.  To our knowledge, no study has been published 
examining ambulatory CASP in dialysis patients.  Finally, we sought to determine the utility 
of interdialytic office brachial and central BP measurement in predicting ambulatory BP 
parameters.   
SUBJECTS AND METHODS 
Patient and Control Selection 
The study was approved by the Research Ethics Committee of the University of Cape Town,
South Africa. Cases were selected if they were on maintenance dialysis ≥ 3 month’s 
duration and were able to sign informed consent. 66 Prevalent HD and 8 prevalent peritoneal
dialysis (PD) patients  18 years old were enrolled from Groote Schuur Hospital, Cape Town
giving a total number of recruits of 75. Patients were excluded if they were pregnant or
planning a pregnancy, had sustained arrhythmias or prior coronary stenting. One patient was
excluded for loss to follow-up, thus the final case sample was 74 participants. Age, sex and 
smoking matched healthy controls from the same residential area as cases were selected if
they were free from cardiovascular disease with normal clinical and laboratory examinations
(including eGFR ≥60ml/min and urinary albumin excretion ≤2.5mg/mmol creatinine). 27
Controls were screened, 5 being excluded for hypertension and 2 for low-grade proteinuria
giving a final control sample size of 20.
Laboratory Data 
The following clinical and demographic parameters were recorded on entry to the study:  
blood pressure, cardiac rhythm, age, sex, ethnicity (patient-reported), body mass index 
(BMI), time on dialysis, dialysis modality, smoking habits, history of atherosclerotic 
vascular disease or diabetes, and medication history.  All relevant routine quarterly 
laboratory parameters (haemoglobin, albumin, calcium, phosphate, alkaline phosphatase, 25-
OH-Vitamin D, parathyroid hormone and total cholesterol) on each patient for the two years 
prior to enrolment was recorded and averaged.  Controls underwent serum creatinine testing 
with estimated glomerular filtration rate as well as urinary albumin excretion quantification 
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calcium and phosphate intake was estimated using a 24hr food recall questionnaire and food 
frequency tables.   
 
Ambulatory and Office Blood Pressure Monitoring 
The BPro® Radial Pulse Wave Acquisition Device and A-PULSE CASP® Software 
(HealthStats, Singapore) system uses an N-Point Moving Average method to non-invasively 
derive CASP from the radial arterial pressure waveform. It is a small, wrist watch-like 
cuffless blood pressure monitor which obtains radial pressure waveforms by applanation 
tonometry and is FDA approved plus carries the CE mark.  For CASP, it has been validated 
against a generalized transfer function method (GTF-CASP [SphygmoCor system, AtCor, 
Sydney, Australia]) using CAFE study data as well as central aortic pressures recorded in 
vivo at the aortic root using a Millar’s SPC‐454D tonometer (Millar’s instruments, Texas 
U.S.A) (22). For BP determination, the BPro™ has been validated against the Association 
for the Advancement of Medical Instrumentation (AAMI) and European Society of 
Hypertension (ESH) protocols and passed both validations (23).  The BPro™ records 
pressure wave forms calibrated to the brachial BP and samples up to 96 X 10 second blocks 
of time, over 24 hours.  This provides a 24 hour profile and summary of an individual’s 
systolic, diastolic and mean arterial pressures.  Additionally, with help from the 
manufacturer, we were able to convert the ABPM data into ambulatory CASP readings.  
Practically, the device was applied as a wrist watch on the non-dominant arm or that which 
did not contain an AVF on the interdialytic day for HD patients or at a routine visit for PD 
patients.  The device was then calibrated to office BP - brachial blood pressure obtained via 
use of the MC3000 oscillometric device (HealthStats) according to the recommended ESH 
protocol (24).  The device was then connected to the software and real time pulse wave 
morphology captured.  Thereafter, it was worn by the individual for a 24 hour period 
whereupon the device was retrieved and ambulatory data captured.       
 
Abdominal X-Ray 
A standard technique of exposing the lateral lumbar spine in standing position (with 100 cm 
film distance, 94 KVP, and 33–200 mAs) was used. Calcific deposits in the abdominal aorta 
were scored as described by Kaupilla (25), by a single experienced clinician (RF) blinded to 
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Cardiac CT  
Images were acquired using the Philips Brilliance 64 slice MDCT Scanner.  A standard 
protocol was used as follows: tube voltage, 120 kV; tube current, 55 mAs; detector 
collimation, 40 × 0.625 mm; gantry rotation, 400 ms.  CT data were transferred to the Philips 
Extended Brilliance Workstation Version 4.0.2.145 for analysis and CCS was calculated 
with the Agatston algorithm (26).  All scans were evaluated by a single experienced 
radiologist (SM) and the intra-reader variability was tested and was below 10%. 
Echocardiography 
Assessment of the left ventricular mass was done via use of M-mode echocardiography and 
this was calculated using the Penn convention (27).  Left ventricular hypertrophy was 
defined as >125 g/m
2 
in males and >110 g/m
2
 in females as per ESH guidelines (28).  All 
scans were obtained and evaluated by a single experienced cardiologist, who was blinded to 
clinical data (AL). 
Statistical analysis 
Normality was determined with the Shapiro-Wilk test. Continuous variables are expressed as 
mean ± SD or median and inter-quartile range (IQR) and compared with the two-tailed 
independent Student’s t-test and Mann-Whitney test as appropriate.    Dichotomous data are 
presented as percentages and compared with Chi-square tests.  To evaluate the utility of the 
AXR in predicting coronary calcification, the receiver operator characteristic (ROC) curve 
analysis was used to calculate the area under the curve in relation to a CCS of ≥1 and ≥10.  
Associations between elevated coronary calcium scores and various exposures are presented 
as prevalence ratios and 95% confidence intervals (CI) and were estimated using generalized 
linear modeling.  Subjects of African ethnicity were classified as Black and the remainder of 
subjects were classified together as non-black for the purposes of the analysis.  All analyses 
were conducted using Stata 12.0 Statistical Software (College Station, TX, USA). 
With respect to control size calculation, there is no published data on coronary calcification 
scores in the South African population.  Using data from a study published in Brazil with a 
comparable younger dialysis patients (29), the proportion of patients with a coronary calcium 
score of <100 was 48%.  In the Multi-Ethnic Study of Atherosclerosis (MESA) (30), the 
distribution of coronary artery calcium score by race, gender, and age was evaluated in 
asymptomatic individuals free of cardiovascular disease.  Given that the 90th percentile for 
coronary calcium score in those aged 45-54 years  in whites was 8 for women and 110 for 
men and in blacks 9 for women and 45 for men, we considered it reasonable to assume that 
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Using these proportions, we calculated a sample size of 13 controls and 75 patients but given 
the uncertainty surrounding the proportions, we chose to include 80 cases and 20 controls. 
 
RESULTS 
The study population consisted of 74 Cases and 20 Controls in the final analysis.  Table 1 
shows baseline characteristics for cases.  Blacks had a mean age of 41.6 (SD 11.1) and were 
53% female; Non-Blacks had a mean age of 41.9 (SD 10.0) and were 61.8% female, p=0.9 
and 0.4 respectively.  At enrolment, 39 (52.7%) had been exclusively on HD, 5 (6.8%) 
exclusively on PD and 30 (40.5%) on both modalities.  Calcitriol was being used by 82.9% 
of the cases and this was not different between race groups (p=0.8).    All patients were 
dialysed with a dialysate calcium content of 1.25mmol/L and were on the maximum dose of 
calcium carbonate phosphate binders.  Table 2 shows the estimated dietary calcium and 
phosphorous intake in a sub-study of 20 patients. 
 
Table 1: Baseline Characteristics of cases 
Characteristic N Value Range (SD/IQR) 
Age, mean (years) 74 41.8 10.5 
Women (%) 74 56.8   
Race, self-reported (%)      
   Black 40 54.0   
   Non-Black 34 46.0   
        White 2 2.7   
        Mixed 29 39.2   
        Asian 2 2.7   
        Hispanic 1 1.4   
Body Mass Index, median (kg/m2)  72 23.3 5.4 
Months on Dialysis, median 74 32.0 43.6 
   Haemodialysis 68 27.0 37.6 
   Peritoneal Dialysis 34 17.0 30.0 
Diabetes (%) 74 13.5   
Tobacco Use (%) 74 41.9   
History of Cardiovascular Disease (%) 74 4.0   
ABPM systolic BP, mmHg 72 147.4 33.1 
ABPM diastolic BP, mmHg 72 97.6 21.7 
ABPM Peripheral Pulse Pressure, mmHg 72 49.8 15.4 
ABPM Central Aortic Systolic Pressure, mmHg 72 139.2 31.3 
ABPM Dipping Status (%) 72 5.3 5.5 
LVMI, g/m2 74 180.4 97.4 
LVH      
   By ECHO 74 86.4   
   By ECG 74 70.3   
Ejection Fraction (%) 74 63 12.2 
Plasma Total Cholesterol, mmol/L 66 4.12 0.86 
Plasma Parathyroid Hormone, pmol/L 67 57.1 58.2 
Plasma Alkaline Phosphatase, U/L 67 97.8 85.5 
Plasma Corrected Calcium, mmol/L 63 2.0 0.2 
Plasma Phosphate, mmol/L 64 1.7 0.4 
Plasma PhosphateXCalcium product (mmol/l2) 66 3.43 0.95 
Plasma 25-OH-Vitamin D nmol/L 62 66.8 41.4 
Plasma Albumin, g/L 63 39.7 3.7 
Plasma Haemoglobin, g/dL 64 8.8 1.4 
Patients on treatment with Calcitriol (%) 70 82.9   
Patients on treatment with Ergocalciferol (%) 69 17.4   
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SD, Standard Deviation; IQR, Interquartile range; ABPM, Ambulatory Blood Pressure Monitoring; BP, Blood 
Pressure; LVMI, Left Ventricular Mass Index; LVH, Left Ventricular Hypertrophy 
 
 
Table 2: Estimated dietary calcium and phosphorous intakes 
Population N Calcium Intake, 
mg/day 
SD P-Value Phosphorous Intake, 
mg/day 
SD P-Value 
Blacks 10 401 224 0.3 915 287 0.9 
Non-Blacks 10 527 268 906 399 
Note: Calcium intake is excluding the contribution from calcium-containing phosphate binders. SD, Standard 
Deviation 
Race and vascular calcification 
Table 3 shows the median coronary and abdominal aortic calcium scores by race as well as 
the proportion with calcification by race and quartile/tertile respectively.  Overall, only 
15.5% and 17.5% of black patients had coronary or abdominal calcification respectively 
compared with 67.7% and 57.6% of non-blacks respectively (both comparisons are 
p<0.001).  There was no association between dose of calcitriol and CCS (p=0.8).  Median 
25-OH-Vitamin D levels were not different in blacks (68.4, IQR 70.4) and non-blacks (66.6, 
IQR 42.6), p=0.3.  Controls had no demonstrable VC (p<0.01).   
 
Table 3: Proportion of cases and controls with coronary and abdominal calcification  
  Quartiles of Coronary Calcification Score 
 0 1-9 10-99 ≥100 
Race N Median 
Score 
IQR  Prop 95%CI Prop 95%CI Prop 95%CI Prop 95%CI 
Black cases 39 0 0  84.6 69.594.1 2.6 0.0-13.5 2.6 0.0-13.5 10.3 2.9-24.2 
Non-Black 
cases 
31 66 383  32.3 16.7-51.4 3.2 0.0-16.7 25.8 11.9-44.6 38.7 21.8-57.8 
Controls 20 0 0  100 83.2-100.0 0 0.0-16.8 0 0.0-16.8 0 0.0-16.8 
             
  Tertiles of Abdominal Aortic Calcium Score 
 0 1-6 ≥7 
Race N Median 
Score 
IQR  Prop 95%CI Prop 95%CI Prop 95%CI 
Black cases 40 0 0  82.5 67.2-92.7 12.5 4.2-26.8 5.0 0.1-16.9 
Non-Black 
cases 
33 1 8.5  42.4 25.5-60.8 24.2 11.1-42.3 33.3 18.0-51.8 
Controls 20 0 0  100 83.2-100.0 0 0.0-16.8 0 0.0-16.8 
Prop, Proportion; IQR, Interquartile Range; PR, Prevalence Ratio; 95%CI, 95% Confidence Interval 
 
 
Risk factors for vascular calcification and haemodynamic effects 
Table 4 shows baseline characteristics for all subjects with and without coronary 
calcification and for black race.  Those with coronary calcification (Ca
++
) were older, had 
been on dialysis longer and had more diabetes than those without coronary calcification (Ca 
-).  Black race was associated with less coronary calcification.  Gender, tobacco use, dialysis 
modality, history of cardiovascular disease, LVMI, all BP parameters and all biochemical 
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on CASP was adjusted for by reporting a CASP:SBP ratio.  There was also no difference in 
central BP parameters when comparing groups with and without abdominal aortic 
calcification. 
 
In a pre-specified subgroup analysis, blacks who did develop coronary calcification (n=6) 
had a non-significantly higher blood pressure (systolic BP +18.3mmHg and CASP +27.7%) 
than blacks without coronary calcification (n=33), both p=0.1.   However, there was a higher 
percentage of diabetes (+47%, p<0.001) and known cardiovascular disease (+30.3%, 
p<0.05).  Black subjects with Ca
++
 had higher plasma calcium, phosphate and cholesterol 
although this also did not reach significance (p=0.1).   In non-black subjects, only age was 
significantly associated with Ca
++ 
(P<0.001).    
 
Table 4: Baseline characteristics of cases stratified by presence of coronary calcificatio  and race 
 All Races Blacks 
Variable N Ca - N Ca++ P-
Value 
N Ca - N Ca++ P-
Value 
Age (median) 43 38.3 27 46.0 <0.01 33 39.8 6 48.3 0.1 
Black Race (%) 33 84.6 6 15.4 <0.001 - - - - - 
Gender, m/f ratio 43 1.1 27 0.5 0.1 33 1.1 6 0.5 0.4 
Time on Dialysis before 
inclusion, months 
43 27.0 26 51.0 <0.05 33 27.0 5 27.0 0.7 
Tobacco Use (ever) (%) 43 37.2 27 51.9 0.2 33 33.3 6 50.0 0.4 
Prior cardiovascular Events (%) 43 2.3 27 7.4 0.3 33 3.0 6 33.3 <0.05 
Presence of Diabetes (%) 43 7.0 27 25.9 <0.05 33 3.0 6 50.0 <0.001 
ABPM systolic BP, mmHg 43 145.8 26 150.1 0.6 33 143.5 5 161.8 0.1 
ABPM diastolic BP, mmHg 43 97.7 26 97.3 0.9 33 94.5 5 104.1 0.2 
ABPM Peripheral Pulse Pressure, 
mmHg 
43 48.0 26 52.8 0.2 33 47.3 5 59.8 0.1 
ABPM Central Aortic Systolic 
Pressure, mmHg 
43 137.6 26 141.8 0.6 33 133.5 5 161.2 0.1 
ABMP CASP/SBP ratio  43 0.9 26 0.9 0.5 33 0.9 5 0.9 0.2 
ABPM Central Pulse Pressure, 
mmHg 
43 39.9 26 44.5 0.2 33 47.0 5 59.8 0.1 
Plasma Total Cholesterol, 
mmo/L 
39 4.0 25 4.4 0.1 31 4.0 5 4.5 0.2 
Plasma Parathyroid Hormone, 
pmol/L 
39 66.0 25 65.0 0.4 31 57.9 5 67.8 0.3 
Plasma Alkaline Phosphatase, 
U/L 
39 99.8 25 79.2 0.1 31 111.0 5 79.0 0.4 
Plasma Corrected Calcium, 
mmol/L 
38 2.0 25 2.0 0.4 30 2.0 5 2.2 0.2 
Plasma Phosphate, mmol/L 39 1.6 25 1.8 0.1 31 1.6 5 2.0 0.1 
Plasma PhosphateXCalcium 
product 
38 3.2 25 3.7 0.1 30 3.2 5 4.1 0.1 
Plasma 25-OH-Vitamin D 
nmol/L 
37 66.7 23 68.2 0.5 29 66.6 3 98.5 0.6 
Ca -, Coronary Calcium Score = 0; Ca++, Coronary Calcium Score = ≥1; m/f = Male:Female; ABPM, Ambulatory Blood 















Table 5 shows the prevalence ratios of coronary calcification by various categories in a 
model adjusted for age, sex and race as well as an adjusted model.  Time on dialysis, 
presence of diabetes, history of vascular disease and phosphateXcalcium product were 
included in the adjusted model (these being established risk factors for vascular calcification 
in CKD-5D (6-8))  Using generalized linear modeling to investigate independent predictors 
of CCS≥1, the following factors were excluded: gender , time on dialysis , diabetes  and 
phosphateXcalcium product (all non-significant).  Independent predictors of coronary 
calcification were age and history of cardiovascular.  Black race remained an independent 
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Table 5: Univariate and multivariate prevalence ratios of coronary calcium presence for cases 
  UNIVARIATE MODEL 











AGE (Years) <30 12 16.7 1.0 (Ref) 1.0 (Ref) 
 30-39 15 13.3 2.6 (0.4-18.5) 1.03 (1.01-1.05) 
 40-49 27 51.9 5.1 (0.9-27.8)  
 ≥50 16 56.3 5.5 (1.0-30.5)  
RACE (Self Reported) Non-Black 31 67.7 1.0 (Ref) 1.0 (Ref) 
 Black 39 15.4 0.3 (0.2-0.5) 0.14 (0.0-0.53) 
GENDER (M/F) Female 39 46.2 1.0 (Ref) 1.0 (Ref) 
 Male 31 29.0 0.8 (0.6-1.2) 0.91 (0.60-1.39) 
TIME ON DIALYSIS (Years) 0-1.99 19 26.3 1.0 (Ref) 1.0 (Ref) 
 2.0-2.99 17 23.5 0.9 (0.4-1.9) 0.65(0.31-1.38) 
 3.0-5.99 15 53.3 1.1 (0.6-2.1) 0.88 (0.48-1.61) 
 ≥6.0 18 50.0 1.0 (0.5-2.0) 0.83 (0.48-1.61) 
PRIOR CARDIOVASCULAR 
EVENT (Y/N) 
No 67 37.3 1.0 (Ref) 1.0 (Ref) 
 Yes 3 66.7 4.2 (1.4-12.4) 7.5 (1.5-36.7) 
DIABETES (Y/N) No 60 33.3 1.0 (Ref) 1.0 (Ref) 
 Yes 10 70.0 1.17 (0.7-1.9) 0.93 (0.53-1.64) 
CALCIUM/PHOSPHATE 
PRODUCT (mmol/l2) 
<3.0 22 22.7 1.0 (Ref) 1.0 (Ref) 
 3.0-4.49 31 48.4 1.5 (0.9-2.4) 1.31 (0.75-2.30) 
 ≥4.5 10 50.0 1.4 (0.7-2.5) 1.35 (0.68-2.65) 
PLASMA CALCIUM (mmol/L) <2.0 32 37.5 1.0 (Ref)  
 ≥2.0 31 41.9 1.3 (0.9-1.9)  
PLASMA PHOSPHATE (mmol/L) <1.4 16 31.2 1.0 (Ref)  
 1.4-1.8 22 27.2 0.9 (0.3-2.5)  
 >1.8 26 53.9 1.7 (0.8-4.0)  
ABPM SYSTOLIC BP (mmHG) <120 12 25.0 1.0 (Ref)  
 120-139 13 46.2 0.9 0.5-1.6  
 140-159 23 43.5 0.6 0.3-1.2  
 160-179 13 30.8 0.9 (0.5-1.7)  
 ≥180 8 37.5 0.6 (.3-1.4)  
ABPM CASP/SBP RATIO <0.910 15 33.3 1.0 (Ref)  
 0.91-0.929 20 35.0 1.1 (0.6-2.0)  
 0.930-0.939 13 30.8 1.1 (0.6-2.1)  
 ≥0.940 16 62.5 1.4 (0.8-2.5)  
BP DIPPING STATUS (%) ≤0 11 54.6 1.0 (Ref)  
 0.001-4.9 19 47.4 0.8 (0.5-1.3)  
 5-9.9 21 28.6 1.1 (0.6-1.9)  
 ≥10 11 36.4 1.3 (0.7-2.3)  
PLASMA CHOLESTEROL (mmol/L) <4.0 27 22.2 1.0 (Ref)  
 4.0-4.99 29 58.6 1.0 (0.7-1.5)  
 ≥5.0 8 25.0 0.8 (0.5-1.7)  
PLASMA 25-HYDROXY-VIT D 
(nmol/L) 
<50 13 53.9 1.0 (Ref)  
 50-74 21 28.6 1.2 (0.7-2.1)  
 75-89 9 44.4 1.1 (0.7-1.7)  
 ≥90 17 35.3 0.7 (0.4-1.2)  
%CAC+, Percentage with coronary calcium score ≥1; PR (95% CI), Prevalence Ratio (95% Confidence Interval); M/F, 
Male/Female; ABPM, Ambulatory Blood Pressure Monitoring; BP, Blood Pressure; CASP/SBP, Central Aortic Systolic 
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Comparing cases with controls 
Table 6 shows the differences in baseline characteristics between cases and controls.  There 
was no difference with respect to age, gender, race and smoking status.  BP, LVMI and 
CASP were all significantly higher in cases while dipping was significantly lower.  After 
adjustment for SBP, CASP was not different between cases and controls. 
 
Table 6: Baseline characteristics of cases versus controls 
 Cases Controls  
Variable N Value N Value P-Value 
Age (median) 74 41.8 20 39.7 0.4 
Gender, m/f ratio 74 0.8 20 0.8 0.9 
Tobacco Use (%)   74 41.9 20 42.1 1.0 
Black Race (%) 74 54.0 20 50.0 0.8 
ABPM systolic BP, mmHg 72 147.4 20 130.6 p<0.01 
ABPM diastolic BP, mmHg 72 97.6 20 85.8 p<0.01 
ABPM Central Aortic Systolic Pressure, mmHg 72 139.2 20 123.3 p<0.05 
ABMP CASP/SBP ratio 72 0.9 20 0.9 0.9 
ABPM SYS-CASP Difference , mmHg 72 8.3 20 7.3 0.1 
ABPM Dipping Status (%) 72 5.3 18 9.3 p<0.01 
LVMI, g/m2 74 180.4 20 97.3 p<0.001 
LVH (On echo criteria), % 74 86.4 20 5.0 p<0.001 
m/f, male/female; ABPM, Ambulatory Blood Pressure Monitoring; BP, Blood Pressure; CASP/SBP, Central 
Aortic Systolic Pressure/Systolic Blood Pressure; SYS, Systolic Pressure; LVMI, Left Ventricular Mass Index; 
LVH, Left Ventricular Hypertrophy 
Office versus ambulatory blood pressure 
Figure 1 shows the correlation of Office with ambulatory systolic blood pressure.  Office 
systolic BP and CASP correlated well with ambulatory blood pressure (both r=0.9, p=0.9).  
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Abdominal aortic x-ray as a screening test for vascular calcification 
Figure 2 shows the receiver operator characteristics curve for predicting a CCS of ≥10 in 
cases using an abdominal calcification score of 1.  The area under the curve (AUC) was 0.83 
with a sensitivity of 76% and a specificity of 86.7%, resulting in the correct classification of 
82.9% of patients.  Using a cut point of abdominal score ≥2 reduced sensitivity to 56.0% and 
raised specificity to 93.3%.  Using an abdominal score of 1 to rather predict a coronary 
calcium score of ≥1 yielded much the same findings as the first analysis (AUC of 0.82, 
sensitivity of 74.1%, specificity of 88.4% and also correctly classifying 82.9% of patients).  
 
Figure 2: ROC Curve for predicting coronary calcium score ≥1 using abdominal aortic 





This is a prospective cross-sectional study of 74 CKD-5D patients in a South African public 
sector dialysis unit. To our knowledge, this is the first descriptive study of vascular 
calcification in CKD-5D in Sub-Saharan Africa.  The young age of participants represents a 
population selection bias because of stringent public sector dialysis inclusion criteria.  
Patients are selected for state-funded dialysis based on their suitability for transplantation, 
amongst other things.  This also explains the low BMI and low prevalence of diabetes and 
cardiovascular disease in the cohort (table 1).  The low haemoglobin is in keeping with a 
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A key finding in this study was the significantly lower prevalence of coronary calcification 
in blacks versus non-blacks (table 3).  In the USA, a recent cross sectional survey of 
prevalent dialysis patients showed no differences in coronary and thoracic calcification 
between white and black subjects (31).   In the general population, however, significant 
differences exist between the coronary calcium content in white populations of different 
continents (32) and in the rate of coronary (33) and extra-coronary calcification (34) between 
different ethnic groups.  In Africa, genetic and environmental influences may affect mineral 
metabolism and hence cardiovascular risk.   In our cohort, the use of calcitriol was common 
practice but was not different in blacks.  In contrast to other studies from abroad, (35) 25-
Hydroxy-Vitamin D levels were not lower in blacks.  Moreover, estimated dietary calcium 
and phosphate intakes were not different between groups.  Since we are unable to account 
for any external differences between the groups, it may be that inherited differences in 
endogenous inhibitors of calcification exist between blacks and non-blacks.  This requires 
further study. 
The 6 black patients with Ca
++
, had a non-significantly higher blood pressure, more diabetes 
and more cardiovascular disease than blacks without coronary calcification.  Blacks with 
calcification also exhibited a trend to higher calcium and phosphate levels although this was 
also not significant.    The low numbers in this sub-group precluded any meaningful 
multivariate analysis.      
Contrary to our expectations, the presence of VC or CKD-5D was not associated with higher 
ambulatory or office CASP when adjusting for SBP with an ABPM CASP/SBP ratio of 
0.943 for Ca - versus 0.945 for Ca
++
 , p=0.5 in cases and 0.944 for controls, p=0.9.  The 
reasons for this are unclear but it may be that VC is not directly responsible for aortic 
stiffening and that the association with PWV is not causative since there are many factors 
such as elastin fragmentation, endothelial dysfunction and advanced glycation that affect 
aortic stiffness other than calcification (12).  Alternatively, since vascular micro-
calcifications may be present in uraemic subjects without apparent radiologically visible 
calcium, (36) it is possible that vascular stiffening occurs earlier on and obscures any 
differences in CASP.  However, this does not explain the lack of difference between cases 
and healthy age-matched controls and calls into question the use of the N-Point Moving 
Average method to non-invasively derive CASP.  These results require confirmation using 
established methodologies such as PWV.  Of further interest, is the lack of any relationship 
between vascular calcification and other predictors of outcome in CKD such as LVMI and.  
Since VC predicts outcome so well in other CKD-5D patients, it will be important to follow 















Interdialytic office blood pressure and CASP correlated very well with ambulatory BP 
measurements.  This has important implications since the FDA has called for the inclusion of 
CASP into clinical studies of blood pressure (9).  Non-dipping was particularly prevalent as 
in other studies of CKD (37) and was worse in the cases.  ABPM has been shown to be 
superior to office and intradialytic measurements in predicting outcomes for CKD-5D 
patients (38, 39) and it remains to be determined whether this applies to our cohort. 
 
The AXR provided a good screening test for the presence of a CCS ≥1 with an AUC of 0.83.  
This compares favourably to a study from the United States where the AUC using AXR was 
0.78 in predicting a coronary calcium score ≥30 (18).    These findings have important 
implications in providing a cost-effective screening test for vascular calcification in Sub-
Saharan Africa where resources are particularly limited. 
 
There are several limitations to our study.  First, the patients in our cohort are young and one 
cannot be certain whether these findings would be reproduced in an older cohort of patients 
more similar to what has been reported on from abroad.  Second, whites were poorly 
represented in our cohort and further study in this population would help to explore the 
differences between race groups more fully.  Third, we were not able to measure PWV in our 
study and this would have helped to reconcile the lack of effect of VC and CHD-5D status 
on CASP.  Fourth, we were unable to measure calcium flux in the different race groups 
which could affect the prevalence of vascular calcification.  Finally, while we are attempting 
to investigate the variation in dietary intake of calcium and phosphate between race groups, 
we lack a locally validated and accurate system for quantifying intake, and this needs to be 
confirmed in a larger study.  The strengths of our study include the prospective nature, the 
inclusion of virtually all available patients in the unit, the very low rate of dropout and the 
inclusion of a control group. 
 
In conclusion, in South African dialysis patients, black race appears to confer significant 
protection against the presence of coronary calcification.  This requires further investigation 
as well as confirmation in other cohorts.  Vascular calcification is not associated with 
changes in central aortic systolic pressure.  Interdialytic office blood pressure and central 
aortic systolic pressure, when measured according to ESH standards, correlate very well with 
ambulatory measurements.  Finally, the lateral abdominal x-ray is a good screening test for 
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PATIENT INFORMATION AND INFORMED CONSENT: CASES 
 
STUDY TITLE: “The impact of vascular calcification on ambulatory and central aortic blood 
pressure in a South African dwelling dialysis population” 
INTRODUCTION 
You are invited to participate in this study.  This information will help you decide if you would like to 
participate. Before you agree, you should fully understand what is involved. If you have any questions, 
which you do not understand, please do not hesitate to discuss this with the study doctor. You should 
not agree unless you are completely happy about this study. 
 
WHY IS THIS STUDY BEING DONE? 
You are invited to participate in this research study.  You have previously advanced chronic kidney 
disease and as such, require dialysis regularly in order to prolong life.  It is a fact that people on 
dialysis suffer more from diseases of the heart and blood vessels (cardiovascular disease) than the 
general population.  Large amounts of calcium build up in their blood vessels and it is likely that this is 
related to the increased chances of cardiovascular related death.  Recent research has suggested that 
the link may be through a higher blood pressure in the great vessels connected to the heart.  We would 
like to examine this link in our unit and therefore request your participation in this research. 
 
WHY ARE YOU BEING ASKED TO TAKE PART? 
As you are on long term dialysis, you are at risk of calcium build up and are thus a good person for us 
assess. 
 
WHAT IS THE DURATION OF THE STUDY AND WHAT PROCEDURES WILL BE PERFORMED? 
If you decide to participate, you will be one of 100 participants. 
The study will be running for approximately 18 months, however, it will take 1 month or less to acquire 
the necessary information from you.  Once you have agreed to participate, you be required to wear a 
device similar to a wrist watch for about 24 hours.  This will gather information on your blood pressure 
and is not painful in any way.  Thereafter, we will arrange for you to have a special CT scan of your 
heart and a plain x-ray of your abdomen that we use to determine the amount of calcium in your blood 
vessels.  Also, we will arrange a special ultrasound of your heart to look for the effects of high blood 
pressure on the heart muscle.  Ideally, we would like to repeat these measurements after a period of 1 
year in order to assess for any change over time. 
 
 
WILL THIS INCONVENIENCE ME IN ANY WAY? 
Participation in the study will mean having to attend hospital between 2 and 4 extra times on the days 
in between your dialysis days.  Every effort will be made to accommodate your needs in terms of timing 
and an amount of R50 will be given to compensate you for transport costs if you come on a non-
dialysis day and R150 for attendance at 2 Millitary hospital. 
 
WHAT WILL HAPPEN IF YOU DECIDE NOT TO TAKE PART IN THE STUDY? 
Your participation is entirely voluntary and you can refuse to participate or stop at any time without 
stating a reason. Your withdrawal will not affect your access to future medical care. The investigator 
retains the right to withdraw you from the study if it is your best interest or you do not follow the 











WHAT ARE THE RISKS AND DISCOMFORTS OF THIS STUDY? 
The only risk incurred in the study is the extra exposure to radiation that you will receive as a result of 
the CT scan and X-ray.  However, the amount of radiation is small and well within that recommended 
to be safe by expert authorities.  Blood tests are unlikely to be required but may result in a bruise at the 
puncture site, swelling of the vein, infection, or bleeding. In experienced hands this is highly unlikely 
and only minor discomfort may occur.  
ARE THERE BENEFITS TO YOU FOR BEING IN THIS STUDY? 
There may be benefits to you if we find your blood pressure is inadequately controlled and we can thus 
give this information to your doctor with your permission.  The benefits of this study may impact future 
patient care positively but ultimately, this may not affect you. 
WHAT WILL HAPPEN WHEN THE STUDY IS OVER? 
With your permission, your results will be shared with the doctor responsible for your care. Any
information collected about you will be kept securely and no information will be divulged to any third 
party without your prior consent or as required by law.  No blood samples will be stored
HAS THE STUDY RECEIVED ETHICAL APPROVAL?
The study protocol has been approved by the Research Ethics Committee of the University of Cape
Town, and the Medicines Control Council of South Africa.
ARE THERE ANY WARNINGS OR RESTRICTIONS FOR MY ACTIVITY?
No. 
INSURANCE AND FINANCIAL ARRANGEMENTS 
All the study doctors are covered by insurance. If any trial related injury occurs, UCT has a No Fault 
Insurance Policy for trial-related injuries. 
The policy states: 
“ The University of Cape Town (UCT) undertakes that in the event of you suffering any significant 
deterioration in health or well-being, or from any unexpected sensitivity or toxicity, that is caused by 
your participation in the study, it will provide immediate medical care. UCT has appropriate insurance 
cover to provide prompt payment of compensation for any trial-related injury according to the 
guidelines outlined by the Association of the British Pharmaceutical Industry, ABPI 1991. Broadly-
speaking, the ABPI guidelines recommend that the insured company (UCT), without legal commitment, 
should compensate you without you having to prove that UCT is at fault. An injury is considered trial-
related if, and to the extent that, it is caused by study activities. You must notify the study doctor 
immediately of any side effects and/or injuries during the trial, whether they are research-related or 
other related complications. 
UCT reserves the right not to provide compensation if, and to the extent that, your injury came about 
because you chose not to follow the instructions that you were given while you were taking part in the 
study. Your right in law to claim compensation for injury where you prove negligence is not affected. 
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SOURCE OF ADDITIONAL INFORMATION 
For the duration of the study you will be under the care of Dr Freercks and Professor‟s Rayner and 
Swanepoel.  If at any time you have symptoms causing you problems or questions please do not 
hesitate to contact them at this telephone number (021) 404 3318.  In addition, you may contact the 
UCT Ethics Committee should you have any concerns about the study or your treatment on tel. 021 
4066626 or at shuretta.thomas@uct.ac.za. 
 
CONFIDENTIALITY 
All information during the course of the trial is strictly confidential. Each patient will be allocated a study 
number – only investigators will be aware of the link between the hospital folder number and study 
number.  Data will be reported in scientific journals, but will not include information that identifies you.   
It is important that the Medicines Control Council of South Africa and the Research Ethics Committee 
of the University of Cape Town be able to review records of the trial, but only in relation to their 
regulatory obligations. 
The Protocol of this clinical trial was submitted for approval to the University of Cape Town Research 
Ethics Committee, a research ethics committee registered with the National Health Research Ethics 
Council. The study has been structured in accordance with the Guidelines on Clinical Trials and Ethics 
in Health Research, published by the Department of Health and the Declaration of Helsinki 2008.  
 
INFORMED CONSENT 
I hereby confirm that I have been informed by the study doctor, Dr Freercks or Prof‟s 
Rayner/Swanepoel about the nature, conduct, benefits and risks of this clinical trial. I have also 
received, read, and understand the written Patient Information and Consent form. 
I am aware that the results of the trial will be anonymously processed into a trial report. 
I may, at any stage, withdraw my consent and participation without prejudice. 
I have had sufficient opportunity to ask questions declare myself prepared to participate in the trial. 
 
Patient’s Name: ……………………… …………….(print) 
Patient’s Signature:…………………………………… Date: …………… 
Study Doctor’s Name: …………………………………   (print) 
Study Doctor’s Signature: ……………………………..Date: ……………. 
Witness Name:       ……………………………………… (print) (Required only if interpreter used) 


















PATIENT INFORMATION AND INFORMED CONSENT: CONTROLS 
STUDY TITLE:“The impact of vascular calcification on ambulatory and central aortic blood pressure in 
a South African dwelling dialysis population”
INTRODUCTION 
You are invited to participate in this study.  This information will help you decide if you would like to 
participate. Before you agree, you should fully understand what is involved. If you have any questions, 
which you do not understand, please do not hesitate to discuss this with the study doctor. You should 
not agree unless you are completely happy about this study. 
WHY IS THIS STUDY BEING DONE? 
You are invited to participate in this research study. The patients enrolled in this study have previously
been diagnosed with advanced chronic kidney disease and as such, require dialysis regularly in order
to prolong life. It is a fact that people on dialysis suffer more from diseases of the heart and blood
vessels (cardiovascular disease) than the general population. Large amounts of calcium build up in
their blood vessels and it is likely that this is related to the increased chances of cardiovascular related
death. Recent research has suggested that the link may be through a higher blood pressure in the
great vessels connected to the heart. We would like to examine this link in our unit and are therefore
enrolling patients from our unit to participate. 
WHY ARE YOU BEING ASKED TO TAKE PART?
It would greatly add to the conclusions drawn from this study to be able to compare our findings with
healthy subjects from the same population.  Although you are apparently healthy, it will be necessary to
conduct a thorough physical examination and performs some simple tests to confirm this.
WHAT IS THE DURATION OF THE STUDY AND WHAT TESTSWILL BE PERFORMED?
If you decide to participate, you will be one of 100 participants of which 80 will be patients and 20 will
be healthy controls such as yourself.
The study will be running for approximately 18 months, however, it will take 1 month or less to acquire
the necessary information from you. Once you have agreed to participate, you will undergo a thorough
physical examination to exclude any chronic diseases as well as a simple urine dipstick. You will also
be required to have one blood test to ensure that your kidney function id within normal limits for your
age. If all of the above is satisfactory, you be required to wear a device similar to a wrist watch for
about 24 hours. This will gather information on your blood pressure and is not painful in any way. 
Thereafter, we will arrange for you to have a special CT scan of your heart which will allow us to detect
the degree of calcium buildup present, if any.  year in order to assess for any change over time.
WILL THIS INCONVENIENCE ME IN ANY WAY? 
Participation in the study will mean having to attend hospital between 2 and 4  times  Every effort will 
be made to accommodate your needs in terms of timing and an amount of R100 per visit will be given 
to compensate you for transport costs.  
WHAT WILL HAPPEN IF YOU DECIDE NOT TO TAKE PART IN THE STUDY? 
Your participation is entirely voluntary and you can refuse to participate or stop at any time without 
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retains the right to withdraw you from the study if it is your best interest or you do not follow the 
guidelines and regulations of the trial. 
 
WHAT ARE THE RISKS AND DISCOMFORTS OF THIS STUDY? 
The only risk incurred in the study is the extra exposure to radiation that you will receive as a result of 
the CT scan.  However, the amount of radiation is small and well within that recommended to be safe 
by expert authorities.  Blood tests may result in a bruise at the puncture site, swelling of the vein, 
infection, or bleeding. In experienced hands this is highly unlikely and only minor discomfort may occur.  
 
ARE THERE BENEFITS TO YOU FOR BEING IN THIS STUDY? 
There are no direct benefits to you other than your contribution to our research.  If the amount of 
calcium is considered to be high in your arteries, you will be referred to your health care provider with 
the result for further workup and care.  The benefits of this study may impact future patient care 
positively but ultimately, this may not affect you. 
 
WHAT WILL HAPPEN WHEN THE STUDY IS OVER? 
With your permission, your results will be shared with the doctor responsible for your care.   Any 
information collected about you will be kept securely and no information will be divulged to any third 
party without your prior consent or as required by law.  No blood samples will be stored 
 
HAS THE STUDY RECEIVED ETHICAL APPROVAL? 
The study protocol has been approved by the Research Ethics Committee of the University of Cape 
Town, and the Medicines Control Council of South Africa. 
 
ARE THERE ANY WARNINGS OR RESTRICTIONS FOR MY ACTIVITY? 
No. 
 
INSURANCE AND FINANCIAL ARRANGEMENTS 
All the study doctors are covered by insurance. If any trial related injury occurs, UCT has a No Fault 
Insurance Policy for trial-related injuries.  
The policy states:  
 
“ The University of Cape Town (UCT) undertakes that in the event of you suffering any significant 
deterioration in health or well-being, or from any unexpected sensitivity or toxicity, that is caused by 
your participation in the study, it will provide immediate medical care. UCT has appropriate insurance 
cover to provide prompt payment of compensation for any trial-related injury according to the 
guidelines outlined by the Association of the British Pharmaceutical Industry, ABPI 1991. Broadly-
speaking, the ABPI guidelines recommend that the insured company (UCT), without legal commitment, 
should compensate you without you having to prove that UCT is at fault. An injury is considered trial-
related if, and to the extent that, it is caused by study activities. You must notify the study doctor 
immediately of any side effects and/or injuries during the trial, whether they are research-related or 












UCT reserves the right not to provide compensation if, and to the extent that, your injury came about 
because you chose not to follow the instructions that you were given while you were taking part in the 
study. Your right in law to claim compensation for injury where you prove negligence is not affected. 
Copies of these guidelines are available on request 
SOURCE OF ADDITIONAL INFORMATION 
For the duration of the study you will be under the care of Dr Freercks and Professor‟s Rayner and 
Swanepoel.  If at any time you have symptoms causing you problems or questions please do not 
hesitate to contact them at this telephone number (021) 404 3318.  Additionally, you can contact the 
UCT ethics committee should you have any concerns regarding the project or your treatment: Tel: 
021 406 6626 or via email at shuretta.thomas@uct.ac.za. 
CONFIDENTIALITY 
All information during the course of the trial is strictly confidential. Each patient will be allocated a study 
number – only investigators will be aware of the link between the hospital folder number and study 
number.  Data will be reported in scientific journals, but will not include information that identifies you.   
It is important that the Medicines Control Council of South Africa and the Research Ethics Committee
of the University of Cape Town be able to review records of the trial, but only in relation to their
regulatory obligations.
The Protocol of this clinical trial was submitted for approval to the University of Cape Town Research
Ethics Committee, a research ethics committee registered with the National Health Research Ethics
Council. The study has been structured in accordance with the Guidelines on Clinical Trials and Ethics
in Health Research, published by the Department of Health and the Declaration of Helsinki 2008. 
INFORMED CONSENT 
I hereby confirm that I have been informed by the study doctor, Dr Freercks or Prof‟s
Rayner/Swanepoel about the nature, conduct, benefits and risks of this clinical trial. I have also
received, read, and understand the written Patient Information and Consent form.
I am aware that the results of the trial will be anonymously processed into a trial report.
I may, at any stage, withdraw my consent and participation without prejudice.
I have had sufficient opportunity to ask questions declare myself prepared to participate in the trial. 
Patient’s Name: ……………………… …………….(print) 
Patient’s Signature:…………………………………… Date: …………… 
Study Doctor’s Name: …………………………………   (print) 
Study Doctor’s Signature: ……………………………..Date: ……………. 
Witness Name:  ……………………………………… (print) (Required only if interpreter used) 
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